What is CING's current stock price?

CING (Cingulate Inc.) is currently trading at $4.98 with a market cap of $27.9M.

What sector is Cingulate Inc. in?

Cingulate Inc. (CING) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CING a good stock to buy?

Analysts have a Buy consensus on CING with a price target of $10.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CING Cingulate Inc.

Healthcare

$4.98+0.00%OpenMarket Cap: $27.9M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.32

P/S

0.00

EV/EBITDA

-0.28

DCF Value

$0.05

FCF Yield

-78.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-365.2%

ROA

-89.8%

ROIC

-91.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-9.3M	$—
Q4 null	$0.00	$-6.3M	$—
FY null	$0.00	$-22.4M	$—
Q3 null	$0.00	$-7.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-04-08

Roth CapitalBuy

2026-03-23

Ascendiant CapitalBuy

2025-12-08

Roth CapitalBuy

2025-11-19

Roth CapitalBuy

2025-10-15

Trading Activity

Insider Trades

View All

Silva Raul R.officer: EVP and CSO

SellFri May 08

Silva Raul R.officer: EVP and CSO

SellWed Mar 11

Silva Raul R.officer: EVP and CSO

SellWed Mar 11

Schaffer Shane J.director, officer: Chief Executive Officer

SellWed Mar 11

Schaffer Shane J.director, officer: Chief Executive Officer

SellWed Mar 11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.81

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Peers